Comparison of the hematological effects of a sustained release chitosan formulation of pentoxifylline with a commercial formulation.
In the present study the hematological effects of a sustained release chitosan formulation of pentoxifylline (CAS 6493-05-6) were examined and compared with those of a commercial product. The study was carried out on 12 healthy volunteers. Both formulations were tolerated well clinically. The results demonstrated no antiaggregatory effect of the two different formulations of pentoxifylline in platelet rich plasma. Both drugs resulted in a decrease of plasma fibrinogen levels. A remarkable side effect of the new formulation was mild basophilia, without any clinical problems.
Yamac
K
K
Hematology Unit, Faculty of Medicine, Gazi University, Ankara, Turkey.
Kaptan
K M
KM
Beyan
C
C
Teksin
Z S
ZS
Ağabeyoğlu
I T
IT
Gökgöz
L
L
D000328:Adult; D001773:Blood Cells / Q000187:drug effects*; D002686:Chitin / Q000031:analogs & derivatives*; D048271:Chitosan; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D010314:Partial Thromboplastin Time; D010431:Pentoxifylline / Q000008:administration & dosage / Q000494:pharmacology*; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D011517:Prothrombin Time; D013918:Thrombin Time
D003692:Delayed-Action Preparations; D004337:Drug Carriers; D010726:Phosphodiesterase Inhibitors; D002686:Chitin; D005340:Fibrinogen; D048271:Chitosan; D010431:Pentoxifylline